Please Note: This trial is no longer enrolling new participants
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
| Protocol No. | A081105 | Scope | National |
|---|---|---|---|
| Principal Investigator | Shadia Jalal | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
